|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Primary SS is considered the crossroad between autoimmunity and lymphoproliferation, since approximately 5% of patients develop NHL associated lymphomas.
|
31464663 |
2019 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
We have demonstrated that IFN-free DAA treatment of HCV can improve or even cure NHL. miRNA-26b-levels could be a potentially useful biomarker to predict lymphoma response in HCV-NHL patients.
|
31180334 |
2019 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Our findings showed BMI, and BMI in early adulthood (aged 18-21 years) is associated with the risk of Hodgkin's and non-Hodgkin's lymphoma (HL and NHL), diffuse large beta-cell lymphoma (DLBCL), Leukaemia including acute and chronic myeloid lymphoma (AML and CML), and chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM).
|
30753270 |
2019 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Despite the classic approach "solid cancer first", due to the advanced stage of lymphoma we first started the chemotherapy of NHL.
|
29419687 |
2018 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
The most common HCV infection related B-NHL subtypes include MZL and DLBCL lymphomas.
|
28149648 |
2017 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Areas covered: This article focuses on chronic lymphocytic leukemia (CLL) as a representative for indolent lymphomas and paradigmatic for the tremendous progress in treating B-NHL on the one hand and diffuse large B-cell lymphoma (DLBCL) as a representative for aggressive lymphomas and paradigmatic for many unsolved problems in lymphoma treatment or the other hand.
|
28494631 |
2017 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Results A total of 140 patients with various types of B-NHL, including 74% with diffuse large Bcell lymphoma, were analysed.
|
28144804 |
2017 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Integrating these findings is important for constructing comprehensive models of NHL pathogenesis, which could yield novel targets for therapy and strategies for lymphoma prevention in certain populations.
|
27115168 |
2016 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In this study, we carried out a CNV analysis using GWAS data from 681 NHL cases and 749 controls to explore the relationship between common structural variation and lymphoma susceptibility.
|
25133503 |
2014 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Genotype distributions were studied in 213 lymphoma Caucasian patients (193 non-Hodgkin/NHL and 20 Hodgkin lymphoma/HL) and 214 controls, residents in a region of Southeast Spain.
|
23818366 |
2013 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We used a panel of 193 formalin fixed tissues of lymphoma cases consisting of 55 cases of HL and 138 cases on several B-NHL entities.
|
22672495 |
2012 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Treatment of patients with relapsed or refractory low grade follicular B-NHL lymphoma with rituximab (chimeric anti-CD20 mAb) has resulted in approximately 50% response rate.
|
19885551 |
2009 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
These results indicate that in vitro chemosensitivity testing and gene expression profiling can successfully be utilised to analyse in vivo drug response in patients with leukemic NHL's and can be used to explore new pathway models of drug-induced cell death in vivo which are independent of different lymphoma subtypes and different treatment regimens.
|
16213748 |
2006 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Results showed a clear difference in TGF 1 expression in patients with NHL depending on the subtype of the lymphoma, suggesting its significant role in the pathomechanism of this group of malignant diseases as well as its potential value as a prognostic factor.
|
14704634 |
2004 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
In this article, we will demonstrate that the plasmatic level of soluble HLA-G was significantly increased in 70% of B chronic lymphocytic leukemia, 53% of non-Hodgkin B lymphoma (B-NHL), and 45% of T-NHL.
|
14602240 |
2003 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
The pathologic heterogeneity of AIDS-NHL is correlated with the heterogeneity of the molecular lesions associated with these lymphomas.
|
12055673 |
2002 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Conversely, the remaining systemic AIDS-NHLs and AIDS-primary central nervous system lymphomas preferentially fail to express p27(Kip1).
|
12107101 |
2002 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
High grade lymphomas showed markedly decreased p21 expression (3.9 in Hg-NHL vs. 12 in Lg-NHL and 29 in CLL; values expressed as mRNA transcripts x 10(3), p < 0.009). mRNA and protein expression of p27 was considerably higher in CLL than in the lymphomas.
|
11042528 |
2000 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Conversely, mutations of the 5' noncoding region of BCL-6 occur at sustained frequency throughout the clinico-pathologic spectrum of AIDS-NHL and represent the most common genetic alteration presently detectable in these lymphomas.
|
9720713 |
1998 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
A 14-year-old male and a maternally related cousin were diagnosed with X-linked lymphoproliferative disease (XLP) after developing recurrent B-NHL, characterized by long disease-free intervals and absence of an increased chemoresistance of the recurrent lymphomas.
|
9758353 |
1998 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
We report here the histologic, immunologic, cytogenetic, and clinical features of these 8 NHL along with 3 new lymphomas which have appeared in this group (now 117 patients).
|
1829873 |
1991 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|